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The dynamic changes in cytokine responses in 
CoVID-19: a snapshot of the current state of 
knowledge
“The role of cytokines in COVID-19” online symposium was presented on 18 June 2020 by the NIH/FDA 
Immunology and Cytokine Interest Groups and was purposed to discuss our rapidly changing understanding 
of COVID-19-related cytokine responses in different stages of infection, including the etiologies, downstream 
consequences and possible mitigation strategies. The recording is available at https://nci.rev.vbrick.com/
sharevideo/03106730-66cc-47ba-870b-f6e6274a998a.
The symposium was opened by Anthony Fauci, Director of the National Institute of Allergy and 
Infectious Diseases at the US National 
Institutes of Health (NIAID, NIH), and 
Janet Woodcock, Director of the Center 
of Drug Evaluation and Research, Food 
and Drug Administration (CDER, FDA) 
and currently leading the therapeutics 
component of Operation Warp Speed. 
Fauci briefly reviewed the current 
status of the coronavirus disease 2019 
(COVID-19) pandemic, noting that 
the worldwide incidence had grown to 
8 million cases and more than 300,000 
deaths, with >120,000 fatalities in the USA 
alone (incidence on June 18 2020). The 
causative virus, the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), 
is a single-stranded RNA virus that uses 
angiotensin-converting enzyme 2 (ACE2) 
as a cellular receptor. The atomic-level 
conformation of the prefusion spike protein 
of the virus was recently described by 
NIAID Vaccine Research Center scientists 
and colleagues1. He also underscored 
the role of cytokines in the pathogenesis 
of the different clinical presentations of 
COVID-19, ranging from asymptomatic to 
pneumonia, neurological disorders, acute 
respiratory distress syndrome (ARDS), 
cardiomyopathies, sepsis, hypercoagulability, 
multiorgan failure and death, as well as 
the multisystem inflammatory syndrome 
seen in children. Also, the benefit of 
dexamethasone treatment in severe COVID-
19 cases requiring ventilation was discussed, 
which is consistent with the central roles 
of inflammation and a cytokine storm in 
causing serious pathology. Fauci ended 
his talk by calling attention to the multiple 
initiatives undertaken and supported by 
the NIAID to address the COVID-19 
outbreak. Woodcock followed with an 
address that underscored the broad variety 
of clinical presentations of COVID-19, 
thus highlighting the central role of the 
immune response in this disease. She also 
remarked on the apparent geographic 
clusters of disease manifestations and the 
need to better understand possible factors 
in host–pathogen interactions beyond those 
health conditions already identified, such 
as prior innate immune experience and 
subtle differences in ACE2 expression in 
the populations. Lastly, she discussed the 
complexity of the data emerging from the 
multiple clinical trials that are targeting 
the inflammatory process underlying the 
disease, emphasizing the importance of 
establishing clinically relevant biomarkers to 
guide the therapeutic course.
Cytokine response and disease severity
The first scientific session of the meeting 
focused on the changing cytokine response 
over the course of COVID-19 and was 
opened by Miriam Merad (Mount Sinai 
School of Medicine). Merad first reminded 
us that the infection is asymptomatic 
in 80% of adults and most children, but 
20% of patients require hospitalization 
in the intensive care unit (ICU). The 
mortality rate for patients in the ICU is 
25%, with most deaths attributed to severe 
inflammation and embolic complications. 
In agreement with Woodcock’s remarks 
on the importance of biomarkers to better 
target therapeutic efforts, Merad described 
studies using high-dimensional profiling to 
identify early markers that predict disease 
severity. In one study, her group selected 
a platform that monitors interleukin (IL)-
6, IL-8, IL-1β and tumor necrosis factor 
(TNF), which are well-established targets 
for anti-inflammatory therapeutics. They 
tested over 1,500 patients on the day of 
hospitalization and then correlated the 
serum cytokine concentrations with disease 
outcome. Her data showed that IL-6, IL-8 
and TNF, and to a lesser extent, IL-1β, were 
elevated at the time of hospitalization, and 
their concentrations correlated with disease 
outcome and mortality, even after correcting 
for age, ethnicity, race and comorbidities, 
suggesting that they could be used to 
identify patients at risk of severe disease2.
The proinflammatory cytokines 
remained elevated throughout the disease 
course unless patients were treated with 
steroids or remdesivir, which reduced 
the level of circulating IL-6. She also 
stressed that IL-6 and TNF are regulated 
independently and thus could be targeted 
in parallel in patients with severe disease. 
Merad then described early results from 
deep-profiling longitudinal studies using 
whole-blood proteomics that identified 23 
clusters of cytokines that are differentially 
expressed in patients with mild disease, 
severe disease without end organ damage 
and severe disease with end organ damage. 
In this broader assessment, patients with 
severe disease had increased IL-6 and other 
proinflammatory cytokines, while those 
with moderate disease had a pattern that 
suggested T cell priming. Lastly, Merad 
suggested that the pattern of cytokine 
response in children with multisystem 
inflammatory syndrome partly resembled 
that of adults with severe disease, as they had 
increased expression of proinflammatory 
cytokines; however, they also had a variety 
of autoantibodies, including some classical 
autoantibodies, but also autoantibodies 
directed to cardiac and endothelial 
antigens that might explain the disease 
manifestations. Importantly, the cytokine 
patterns that were present at the time of 
hospitalization in children as well as adults 
were maintained throughout the disease 
course unless modified by treatment with 
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steroids, remdesivir or immunomodulatory 
therapy and could be correlated with disease 
outcome, suggesting that they can be used to 
guide the therapeutic approach.
John Tsang (NIAID, NIH) then spoke of 
the application of a systems immunology 
analysis of COVID-19. He described 
studies employing cellular indexing of 
transcriptomes and epitopes by sequencing 
(CITE-seq), a single-cell analysis method 
that combines highly multiplexed surface 
protein marker detection with transcriptome 
profiling. The Tsang lab and collaborators 
evaluated peripheral blood mononuclear 
cells (PBMCs) from a longitudinal cohort 
of hospitalized patients with COVID-19 
from Brescia, Italy, taken at the height of 
the outbreak in that region. The patients 
evaluated in this first experiment included 
13 severe or critical patients and 5 age- 
and sex-matched healthy controls. Two 
observations in particular emerged that 
differed from findings reported by other 
investigators. First, whereas previous studies 
suggested that the virus disrupted the type I 
interferon (IFN) signaling pathway, fueling 
speculation that the lack of an early type I 
(and III) IFN response permits rapid viral 
spread and induces hyperinflammatory 
responses, this study identified a clear type 
I IFN signature across major immune cell 
subsets in patients with COVID-19. These 
findings suggest that a careful evaluation of 
the patient populations scrutinized across 
different studies should be performed, as the 
timelines for the induction of such responses 
may differ according to disease stage and 
may be further influenced by genetic 
and environmental factors. Furthermore, 
thus far, Tsang has found no evidence 
of T cell exhaustion, as the expanded 
CD8+ T cell clones were found to have 
decreased PD-1 expression in comparison 
with the non-expanded cells in patients. 
This observation again differs from other 
studies that found high amounts of PD-1 
expression on lymphocytes3, indicating 
exhaustion and raising the possibility that 
checkpoint blockade should be considered 
for treatment.
The final seminar in this session was 
given by Frank van de Veerdonk (Radboud 
University Medical Center). The main 
focus of his seminar regarded unique 
aspects of COVID-19 immune pathology; 
specifically, the role of ACE2 in modulation 
of the kallikrein–kinin system. Preliminary 
results suggested that this system has a 
role in the angioedema observed in the 
lungs of COVID-19 patients. Biological 
pathways were evaluated via proteomic 
analysis of serum from patients with 
severe (necessitating ICU care) versus 
more moderate (not requiring ICU care) 
disease, with an initial focus on IL-1 biology 
and autoinflammation and a subsequent 
focus on the kallikrein–kinin system. IL-6 
upregulation was prominent in patients 
with severe disease, which van de Veerdonk 
proposed was a manifestation of the 
strong induction of an autoinflammatory 
loop via IL-1β and the IL-1 receptor (IL-
1R). He proposed that, following SARS 
CoV-2 binding to pathogen recognition 
receptors, pro-IL-1β is induced, processed 
to IL-1β by activated inflammasomes and 
stimulates IL-6 and IL-18 production 
(from pro-IL-18). IL-1β binds to IL-1R on 
monocytes/macrophages, generating the 
autoinflammatory loop and recruitment 
of polymorphonuclear leukocytes. He also 
noted that IL-1α released during tissue 
damage may further contribute to the 
autoinflammatory loop by binding and 
signaling through IL-1R, inducing more 
IL-1β. He further remarked that IL-1 is 
a difficult cytokine to measure (echoing 
others) and that concentrations in plasma 
likely do not reflect those in the lung, 
suggesting that bronchoalveolar lavage 
(BAL) measurements would be important 
in verifying its upregulation at the site of 
primary pathology. Lastly, he remarked on 
the substantial reductions in IL-7R and stem 
cell factor and their potential relevance to 
the commonly observed lymphopenia in 
patients with severe disease, which is of clear 
interest from a therapeutic standpoint. In the 
last part of his talk, van de Veerdonk focused 
on the reduced amounts of serpin family 
A member 12 (SERPINA12) and DPP4 
(CD26) in patients in the ICU versus those 
not in the ICU. Since these factors suppress 
inflammation mediated by kallikreins 
and it is expected that there is positive, 
coordinated stimulation of the kallikrein–
kinin system from increases in IL-1 and 
IL-6 as well as from activated complement, 
the upregulation of the kallikrein–kinin 
system was investigated. Most critically, 
kininogens processed by kallikrein, a serine 
protease, will generate bradykinin (BK) 
or Lys-BK (Fig. 1), which can be further 
metabolized by tissue carboxypeptidases, 
producing des-Arg9-BK (DABK). DABK 
binds to bradykinin 1 receptors (B1Rs) and 
enhances vascular permeability, which can 
lead to local angioedema. Critically, DABK 
is inactivated by ACE2. Because ACE2 is 
internalized by SARS-CoV-2, it is no longer 
present to counter the downstream effects 
of DABK, thus producing angioedema in 
the lung, which potentially explains the 
early ARDS manifestation in these patients. 
Furthermore, IL-1 and inflammation in 
general stimulate increased expression of 
B1Rs, thus upregulating these receptors in 




























Fig. 1 | alveolus during severe CoVID-19 hyperinflammation. ACe2 downregulation by SArS-CoV-2 
is followed by the loss of neutralizing capacity of Lys-[des-Arg9]-bradykinin (bK) in the lung, leading 
to plasma leakage. Subsequently, plasma leakage results in more b1r ligands (des-Arg9-bK) and b2r 
ligands (bradykinin), enhancing vascular permeability and angioedema. CPM, carboxypeptidase M; 
CPN, carboxypeptidase N; HMWK, high-molecular-weight kininogen; LMWK, low-molecular-weight 
kininogen. Figure reproduced with permission from ref. 4, eLife Sciences Publications.
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angioedema. The ensuing plasma leakage 
into the alveolar space allows activation 
of plasma kallikrein–kinin at the site 
of infection. Subsequent production of 
bradykinin results in persistent angioedema 
via bradykinin activation of the bradykinin 2 
receptor (B2R).
This observation led to the hypothesis 
that the kallikrein–kinin system was 
critically involved in lung pathology in 
COVID-19, which was tested by treating 
patients with hypoxia and enhanced oxygen 
requirements with icatibant, an approved 
B2R blocker for hereditary angioedema 
(HAE). Promising effects were observed, 
which will be published soon. This finding 
suggests the need for expanded trials as well 
as the investigation of a longer lasting agent, 
lanadelumab, which blocks plasma kallikrein 
activity and is approved for HAE. In light 
of the findings of this study and data from 
other sources, a treatment protocol based on 
disease stage was proposed4.
Cellular origins of cytokines
The second session commenced with Chen 
Dong (Tsinghua University), who discussed 
his recently published work5 on humoral 
responses in patients with COVID-19. In 
a small cohort, his group readily detected 
IgG1 and IgM antibodies that recognized 
recombinant SARS-CoV-2 nucleoprotein 
and the receptor-binding domain of the 
spike protein (S-RBD) in patient sera 
as compared to serum from healthy 
individuals. In general, antigen-specific 
antibody concentrations were higher in 
individuals recently released from hospital 
(8 patients) as compared to those assayed 2 
weeks after release (6 patients). Longitudinal 
studies on larger patient cohorts will be 
needed to determine the time course and 
duration of humoral responses during 
COVID-19. Somewhat consistent with 
these observations, Luigi Notarangelo 
(NIAID, NIH) noted in a study of more 
than 300 patients from Brescia and Monza 
in northern Italy that the proportion of 
plasmablasts in blood was highest in the 
early stages of COVID-19 and decreased 
with disease course6. Using a pseudovirus 
particle-based neutralization assay, Dong 
found that 13 out of 14 patients developed 
varying levels of neutralizing antibodies with 
specificity for S-RBD. In an independent 
study, 94% of 175 patients developed 
neutralizing antibodies, suggesting that such 
humoral responses are a consistent feature 
of COVID-197. Importantly, antibody titers 
did not correlate with disease duration in 
this study, leaving open the question of the 
contribution of antibodies in determining 
disease progression. It is possible that a 
threshold level of antibody synergizes with 
other features of immune (for example, 
T cell activation and memory formation) 
and inflammatory responses to affect 
disease resolution. It also remains unclear 
to what extent neutralizing antibodies 
persist in convalescent individuals and 
whether they will protect upon rechallenge 
with SARS-CoV-2. In this regard, another 
study reported that 40% of asymptomatic 
individuals and 13% of symptomatic 
individuals became seronegative 8 
weeks after discharge from hospital6. 
This apparently short-lived antibody 
response contrasts sharply with detectable 
SARS-CoV-specific IgG 2 years after 
infection8.
Notarangelo provided a comprehensive 
overview of cellular and cytokine changes 
in the context of disease course and severity 
in the Italian cohort. A recurring pattern 
in COVID-19 is the increased expression 
of proinflammatory cytokines such as IL-6, 
TNF and IL-1β, as well as an IFN-γ signature 
evidenced by expression of the downstream 
cytokine CXCL9; similar observations 
were also presented by Merad and Tsang 
in Session 1. Serum concentrations of 
soluble biomarkers of endothelial cell 
activation (ICAM-1 and VCAM-1) and of 
septic shock (lipopolysaccharide binding 
protein (LBP) and sIL-33R) were also 
significantly elevated in patients with 
COVID-19 and more so in those with 
critical disease who eventually died. In 
an interesting twist, Notarangelo showed 
that, during the course of disease, certain 
inflammatory markers, such as IL-6, did not 
change significantly, whereas others, such 
as soluble IL-33R (sIL-33R) and CXCL10, 
decreased in patients who eventually 
recovered but remained persistently elevated 
in those who succumbed to COVID-
19. Additionally, cytokines associated 
with myeloid differentiation positively 
correlated with disease severity, suggesting 
a contribution of de novo myelopoiesis. 
A striking observation in this study was 
the reduced numbers of CD4+ and CD8+ 
T cells in patients with COVID-19. T 
lymphopenia was evident even in patients 
with mild symptoms, and it reached extreme 
deficits in those with severe disease9. The 
underlying cause of T cell loss is not known 
and will be an important area of future 
research. Notarangelo also pointed out the 
surprising decrease in soluble Fas ligand 
(sFasL) and sCD62L, contrasting with high 
concentrations of sCD25, a biomarker of 
T cell activation. A preprint in bioRxiv also 














Anti-cytokine storm therapy[ ]
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Fig. 2 | the CoVID-19 inflection point of illness. A graphic depiction of the course of illness for the 
up-to-20% of individuals with COVID-19 who develop cytokine storm syndrome (CSS) and respiratory 
distress requiring hospitalization17. Severity of illness is presented along the y axis and time in days along 
the x axis. The participation of both the innate and adaptive immune responses is presented as orange 
and green triangles, respectively, during the different phases of disease. The early stages of infection 
(<5 days of symptoms) give rise to a more prominent respiratory phase in those with early signs of 
CSS, such that an inflection point of illness occurs typically between days 5 and 7 of illness. This interval 
is the time in which targeted immunomodulatory therapy will probably be most beneficial in lowering 
mortality (dashed arrow). MODS, multiorgan dysfunction syndrome. Figure adapted with permission 
from ref. 17, the Journal of rheumatology Publishing.
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activation and cytotoxic responses even in 
seronegative individuals7. Further studies are 
required to understand the contributions of 
such contrasting immune responses to the 
course of COVID-19. Finally, Notarangelo 
provided evidence that reduced expression 
of HLA-DR and CD4 on peripheral blood 
monocytes (the former a biomarker of 
antigen-presenting capacity) correlated 
with disease severity9. By impairing 
antigen presentation and the consequent 
activation of T cells, this cellular phenotype 
could attenuate effective responses during 
SARS-CoV-2 infection. The predictive 
potential of this biomarker remains to be 
determined.
The final speaker in this session, Xiaoyu 
Hu (Tsinghua University), elaborated 
specifically on the nature and origins of 
cytokine responses in COVID-19, focusing 
on the lung myeloid compartment of 
patients. Previous studies have shown that 
the largest population of lung-resident 
alveolar macrophages are of fetal origin and 
are maintained by proliferation in situ10. 
Single-cell RNA sequencing studies of 
BAL fluid from patients with COVID-19 
showed a substantial influx of peripheral 
monocyte-derived macrophages to the 
lungs, with a proportionate reduction in 
the frequency of alveolar macrophages; 
these changes in cell populations correlated 
with disease severity11,12. Recruited 
macrophages primarily expressed high 
amounts of chemokines such as CCL2, 
CCL7 and CCL8 and, with increasing 
disease severity, CXCL10 and CCL3. By 
contrast, typical proinflammatory cytokines 
such as IL-6 and IL-8 that were elevated 
in the periphery were not markedly 
upregulated in these cells. The distinct 
lung-specific responses may contribute 
to COVID-19 lung pathophysiology, for 
example, by CCL2-mediated recruitment of 
macrophages11.
The basis for the dichotomy between 
the chemokine-dominated lung 
macrophage response and the peripheral 
prevalence of more classical inflammatory 
cytokines is not clear. One possibility is 
that the lung microenvironment skews 
macrophage responses toward chemokine 
gene expression. In this scenario, lung 
macrophage responses in other acute 
respiratory syndromes should also be 
similarly skewed. However, it should be 
noted that resident alveolar macrophages 
do not exhibit this pattern, indicating 
that it is not solely a microenvironment 
issue. Alternatively, SARS-CoV-2 infection 
may generate a unique inflammatory 
milieu that promotes the observed gene 
expression pattern. That it is restricted 
to recruited macrophages hints at a role 




The symposium concluded with a session 
that discussed the recent advances in 
managing both the virus infection and the 
associated cytokine storm using biologics 
and drugs to treat the disease and how 
such approaches significantly ameliorated 
disease outcomes. Randy Cron (University 
of Alabama at Birmingham) started off this 
session by reminding us that, long before 
COVID-19 came into the limelight, the 
cytokine storm was already recognized 
as a major issue in the field of immune 
homeostasis. Cytokine storm is an umbrella 
term for several hyperinflammatory 
immune responses that include cytokine 
release syndrome, culture-negative sepsis, 
macrophage activation syndrome and 
hemophagocytic lymphohistiocytosis 
(HLH), among others. Therefore, there are 
several causes of cytokine storm, which can 
be triggered by genetic factors, cancer, viral 
infections and other insults and that need to 
be managed accordingly. Consequently, the 
COVID-19-triggered cytokine storm should 
be manageable using knowledge amassed 
in the past based on the management of 
similar viral infections (Fig. 2). In the course 

































































































Fig. 3 | IFN-α2b treatment accelerates viral clearance and reduces inflammatory Il-6. Patients with confirmed COVID-19 were treated with either Arb alone 
(Arb; 24 patients) or IFN-α2b with or without Arb (IFN; 53 patients). Left, upper respiratory samples were assessed by PCr for the presence of SArS-CoV-2. 
Shown is the proportion of patients who had detectable virus as a function of the day of sampling from symptom onset. The P value for treatment effect was 
assessed using a Cox proportional-hazards model that included age and comorbidities as covariates. right, patients were serially sampled for assessment 
of IL-6 from the day of symptom onset. Values recorded were aggregated across 3 day intervals and shown as the mean ± s.e. P value was assessed using r 
v.3.6.0, and analysis of variance (ANOVA) was used to test for treatment effect, adjusting for age and comorbidities. Figure reproduced with permission from 
ref. 15, International Union of Immunological Societies.
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of his brief but cutting-edge overview of 
the literature, Cron cited a previous study 
wherein the inability of perforin-deficient 
CD8+ CTLs to eliminate LCMV-infected 
target cells resulted in the death of infected 
mice by hyperactivation, but not when 
IFN-γ was neutralized13.
Along these lines, the disruption of other 
genes involved in the cytolytic pathway 
also results in a cytokine storm and lethal 
hyperinflammation. For example, the 
Cron group performed whole-exome 
sequencing of patients who succumbed to 
H1N1 influenza infection and found that 
36% of the 14 individuals in the study had 
mutations in the genes encoding either 
perforin or the lysosomal trafficking 
regulator (LYST). Thus, cytokine storm is 
evidently associated with the failure to clear 
virus-infected target cells and persistent 
T cell stimulation. As a solution, Cron 
summarized a few approaches focused 
on targeting IL-6, IL-1 or JAK/STAT 
proteins to suppress the cytokine storm. He 
concluded his talk by offering alternative 
strategies to reduce hyperinflammation, 
such as JAK inhibitors and glucocorticoids. 
Specifically, the World Health Organization 
initially recommended against the use of 
corticosteroids for COVID-19 based on the 
experiences of SARS and MERS, but recent 
data showed a clear reduction in the need for 
ventilation and in mortality in patients with 
COVID-19 treated with dexamethasone14. 
Steroids are widely available and affordable, 
and, with careful dosing and timing, these 
agents could become powerful tools in 
fighting the cytokine storm triggered by 
SARS-CoV-2.
In the next seminar, Eleanor Fish 
(University of Toronto) put the COVID-
19 pandemic into greater perspective 
by pointing out two other coronavirus 
outbreaks that had preceded SARS-CoV-2, 
namely SARS-CoV in 2002 and MERS-CoV 
in 2012. To control viral infections, the first 
24–72 hours are the most critical, and Fish 
emphasized that the type I IFN response 
by innate cells plays a pivotal role in this 
process. Type I IFNs are powerful because 
they not only act directly on infected cells 
to suppress viral replication but also recruit 
and activate immune cells to clear the virus. 
Notably, the SARS-CoV-2 genome encodes 
genes that suppresses IFN production, such 
as Nsp1, Nsp3, ORF6 and the M proteins. 
Thus, it is evident that viruses are equipped 
with tools to dampen host IFN production, 
and both SARS-CoV-2 and SARS-CoV fail 
to trigger a good type I IFN response.
Along these lines, the Fish group 
demonstrated that SARS-CoV replication 
in vitro could be effectively suppressed 
by IFN alfacon-1 treatment (a synthetic 
IFN-α) and that such an effect was further 
reproduced in a clinical trial when SARS 
patients were subcutaneously injected 
with IFN alfacon-1, resulting in rapid lung 
clearance and substantial improvements 
in various clinical parameters. Translating 
those findings to COVID-19, a clinical trial 
was designed involving 77 hospitalized 
patients with confirmed cases of COVID-
19 in Wuhan, China. In this trial, patients 
were treated with either the antiviral drug 
arbidol (ARB), nebulized IFN-α2b or a 
combination of the two agents. While the 
investigators did not observe any differences 
among patients in the treatment groups 
with respect to body temperature, oxygen 
saturation or blood biochemistry, there was 
a significant difference in viral clearance, as 
IFN-treated patients cleared the virus much 
faster. Notably, IFN-treated patients also 
showed significantly reduced concentrations 
of serum IL-6 and C-reactive protein (CRP) 
(Fig. 3)15. Thus, with the caveat that this trial 
was a non-randomized, small-cohort study, 
the data advocated for using type I IFN as 
an early intervention agent in COVID-19. 
Moreover, type I IFN treatment may prove 
to be more beneficial than other treatments 
because it did not trigger a cytokine storm 
or severe adverse events. Furthermore, it 
may be advantageous over treatment with 
type III IFN, given the systemic spread 
of SARS-CoV-2 from the lungs to the 
vasculature and other organs, as type I IFN 
receptors are expressed on virtually all cells, 
whereas type III IFN receptor expression is 
largely restricted to epithelial cells.
Michail Lionakis (NIAID, NIH) 
presented his recent work utilizing a kinase 
inhibitor to antagonize the COVID-19 
cytokine storm16. The hyperinflammatory 
response in COVID-19 features activation 
of NF-κB and the inflammasome (Nlrp3), 
as evidenced by the increased levels of 
proinflammatory cytokines and chemokines, 
including IL-1β, TNF, IL-6, CCL2 and 
CCL3, among others. Consequently, he 
hypothesized that neutralizing these 
cytokines or their downstream signaling 
would be an effective strategy to suppress 
the COVID-19-associated cytokine storm.
Using mouse models of Bruton’s 
tyrosine kinase (BTK) deficiency and 
pharmacological inhibitors of BTK, the 
Lionakis group previously pinpointed the 
target population of BTK inhibition in 
antifungal host defense to be macrophages, 
not B cells. Ibrutinib is an effective and 
well-tolerated BTK inhibitor that blocks 
B cell receptor signaling and is used 
as a treatment for B cell malignancies 
and inflammatory conditions such as 
graft-versus-host disease. Thus, the 
suppression of macrophages has been 
considered a collateral effect of BTK 
inhibition, resulting in impaired fungal 
immunity as demonstrated by the 
susceptibility to fungal infections in 
a subset of ibrutinib-treated patients. 
Notably, ibrutinib has been reported to 
suppress macrophages by inhibiting the 
activation of both the inflammasome and 
NF-κB, precisely the two downstream 
pathways of the cytokine storm in severe 
COVID-19. These findings led Lionakis 
and his colleagues to hypothesize 
that BTK inhibitors would ameliorate 
hyperinflammation and thus prevent 
clinical deterioration in patients with 
severe COVID-19. The Lionakis group 
hypothesized that the overt immune 
response of SARS-CoV-2-infected alveolar 
macrophages could be inhibited at the 
proximal signaling level by the off-label 
use of a second generation BTK inhibitor, 
acalabrutinib. Such an approach could 
be superior to employing neutralizing 
antibodies specific to individual 
proinflammatory cytokines because it could 
potentially suppress the effect of multiple 
cytokines. In addition, because BTK is not 
expressed in T cells, BTK inhibition would 
limit the effect to macrophages without 
impacting anti-viral T cell effector function.
The results from the first clinical study 
with 19 patients were in line with the 
hypothesis, and some remarkable effects 
were observed for patients with COVID-
19 in the pre-ICU setting16. While patients 
with severe COVID-19 symptoms had 
increased production of IL-6 by CD14+ 
monocytes in blood, acalabrutinib 
treatment substantially improved 
oxygenation, decreased inflammation 
(for example, reduced production of CRP 
and IL-6) and also significantly increased 
lymphocyte numbers in the majority of 
patients. Mechanistically, it was found 
that monocytes but not B cells in patients 
with COVID-19 contained higher basal 
levels of phosphorylated BTK, validating 
that monocyte/macrophage-directed 
BTK inhibition provides the basis of 
suppressing the cytokine storm14. Currently, 
three different BTK inhibitors, including 
acalabrutinib, zanubrutinib and ibrutinib, 
are in clinical trials for treatment of severe 
COVID-19. Further studies will be required 
to validate these clinical findings, which, 
if confirmed, would potentially point to a 
broader use for BTK inhibitors in managing 
hyperinflammatory responses.
Collectively, the talks in this session 
highlighted the multifaceted approaches 
to neutralize cytokine storm in patients 
with COVID-19, and they showcased 
initial successes. Moreover, the results 
further illustrated the necessity of nimble 
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approaches in applying interventional 
strategies, depending on the severity or stage 
of the diseases. Thus, the dosing, timing 
and the selection of the patient group must 
be considered carefully and in the context 
of disease progression. Dexamethasone 
treatment, for example, should be reserved 
for late-stage patients because of its 
immunosuppressive function, whereas type 
I IFNs are clearly suitable for investigation 
in immediate early treatment. Targeted 
suppression of immune cell activities by 
BTK inhibitors has been tested in patients 
requiring oxygen supplementation, but it 
remains unclear whether treatment at earlier 
stages would be even more effective.
Concluding remarks
This conference brought together over 
1,600 scientists from different countries 
and different time zones, demonstrating the 
power of running a virtual conference but 
also documenting the immense worldwide 
interest in COVID-19 biology. Because of its 
great success and the enthusiastic feedback 
that was received, the next COVID-19 
conference organized by the NIH/FDA 
Immunology Interest Group and Cytokine 
Interest Group is already being scheduled, 
and we look forward to broad participation 
in cyberspace in November 2020 to share 
the newest and most exciting research 
on COVID-19 with the international 
community. ❐
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